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The development of novel, non-invasive techniques and standardization of protocols to assess microvascular dysfunction have elucidated
the key role of microvascular changes in the evolution of cardiovascular (CV) damage, and their capacity to predict an increased risk of
adverse events. These technical advances parallel with the development of novel biological assays that enabled the ex vivo identification of
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Introduction
The microcirculation, constituted by pre-arterioles (lumen diam-
eter 100–500mm), arterioles (lumen diameter <100mm), capilla-
ries, and venules, is responsible for most part of the resistance to
flow that modulates blood pressure (BP) and tissue perfusion. As
such, the microvascular structures have key roles in regulating sys-
temic haemodynamics, tissue oxygenation and nutrition, transport
of mediators, exchanges of gases and metabolites to and from tis-
sues.1 Over the years, microvascular dysfunction has been recog-
nized as an early marker of cardiovascular (CV) disease and a key
feature of several clinical manifestations (see the paragraph
‘Historical Perspectives’ in the Supplementary material online,
Addendum).
This has led to the development of novel methods and refinement
of old techniques for the assessment of microcirculation. Reference
values to identify microvascular dysfunction are now being generated
and have the potential to promote harmonization in the interpret-
ation of the results between different laboratories worldwide. In par-
allel, advances have been made in the understanding of the biological
processes regulating microvascular function, including cross-talk be-
tween inflammation, oxidative stress, and cellular ageing pathways.
In this article, we discuss how coronary and peripheral microcircu-
lation can be investigated, the strengths and limitations of each
method, and the reference values that could be used for a correct in-
terpretation of the results. We also provide recent advances on the
molecular mechanisms underpinning microvascular dysfunction, with
particular emphasis on the role of epigenetic alterations regulating in-
flammation, oxidative stress, and cellular ageing pathways. We con-
clude that a more integrated approach to microvascular research
should be adopted in the future, whereby central and peripheral as-
sessment methods should be more frequently combined given their
capacity to provide important complementary information. Such an
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limitations in the development of microvascular active drugs (Take
home figure).
Methods for assessing coronary
microvascular function
Coronary microcirculation can be assessed using invasive and non-
invasive techniques. Although each method has its advantages and
limitations (Table 1), it is now clear that patients may present different
types of coronary microvascular dysfunction (CMD), highlighting the
necessity of a full assessment of coronary microvascular function.
Invasive assessment of coronary
microvascular function
Nearly half of patients undergoing coronary angiography for appro-
priate indications have normal coronary arteries (NCAs) or non-
significant coronary artery disease, as defined by the absence of any
stenosis >_50% of lumen diameter and/or an abnormal fractional flow
reserve (FFR <0.80). Most of these patients has microvascular angina
(MVA), i.e. angina caused by abnormalities of coronary microcircula-
tion.2–5
Coronary microvascular function in the catheterization laboratory
can be assessed by intracoronary vascular reactivity tests, that can be
performed with high reproducibility and safety.6,7 The evaluation usu-
ally begins with the assessment of coronary flow reserve (CFR), the
maximal dilator response to an arteriolar vasodilator, usually adeno-
sine. Furthermore, the response to acetylcholine (Ach) is also
assessed. In normal vessels Ach at lower doses causes vasodilatation
through release of nitric oxide (NO) by the endothelium; at higher
doses, however, it also exerts direct constrictor effects on small cor-
onary arteries via muscarinic receptors on vascular smooth muscle
cells (VSMCs), whichmight occur at lower doses in dysfunctional ves-
sels.8,9 Accordingly, an abnormal coronary microvascular response
to Ach may result from endothelial dysfunction, an increased reactiv-
ity of VSMCs, or both.
Coronary flow reserve
CFR in the cath lab can be assessed by measuring coronary blood
flow (CBF) velocity by an intracoronary Doppler flow wire placed in
the studied coronary artery [usually the left anterior descending
(LAD) artery, Supplementary material online, Figure S1] or using a
temperature sensor-tipped guidewire (CFRthermo) (see the
Supplementary material online, Addendum). Both CFRDoppl and
CFRthermo have been shown to predict clinical events
10,11 and, there-
fore, in the absence of large comparative studies, both methods can
be used to measure CFR. In a recent small study, CFRDoppl showed a
better correlation, compared to CFRthermo, with CFR assessed by
positron emission tomography (PET), in particular in arteries with
no-flow-limiting stenosis. Poor quality traces that did not allow a reli-
able assessment of CFR were, however, more frequent with the
Doppler than the thermodilution method.12 An advantage of the
thermodilution method is that it allows a simultaneous assessment of
FFR to exclude or confirm the presence of haemodynamically signifi-
cant epicardial stenosis.
Adenosine-induced CFR is considered normal when >2.5.
Although some differences in cut-offs may be found among individual
studies, there is now large consensus that an adenosine CFR <2.0
should be considered as definitely demonstrative of an impaired dila-
tation of coronary microcirculation.13 Values between 2.0 and 2.5 are
of borderline clinical significance.
Index of microcirculatory resistance
Coronary microcirculatory function can also be tested by obtaining
the index of microcirculatory resistance (IMR) with the pressure-
thermodilution guidewire catheter (see above and the
Supplementary material online, Addendum). IMR is a measure of cor-
onary microvascular resistance during hyperaemia (usually obtained
with adenosine). Assuming a zero pressure in the coronary vein/right
atrium, IMR is calculated with the formula: IMR = Pd  TmnHyp,
where Pd is the mean coronary pressure in the distal part of the epi-
cardial artery and TmnHyp the Tmn during hyperaemia.
IMR has been shown to be independent of epicardial vascular func-
tion and reproducible. In STEMI patients, IMR provides important
prognostic information regarding the post-MI recovery of ventricular
....................................................................................................................................................................................................................
Table 1 Comparative summary of the strength, weakness, reproducibility and operator-dependency of each method
used to assess coronary microvascular function in clinical practice







Invasive methodsa þ/- - -- þ/-- þ þþþ þþþ
TTDE þþþ þþþ þþþ þþþ þ/- þþ þ/-
MCE þ/- þ/- þ þ þ/- þþ þ/-
PET - - - þ/- þþ þþþ þ/-
CMR þ þ/- - þ þþ þþþ þ/-
(-) = poor for the item; (þ) = sufficient for the item; (þþ) = good for the item; (þþþ) = very good for the item; (þ/-) = between sufficient/poor.
CMR, cardiac magnetic resonance; CMV, coronary microvascular; IIM, invasive intracoronary methods; MCE, myocardial contrast echocardiography; PET, positron emission
tomography; TTDE, transthoracic Doppler echocardiography.
aInclude intracoronary Doppler recording of coronary blood flow velocity and thermodilution method (see text for discussion).
















































































































































function.14,15 Despite reasonable prediction of events and outcomes
following PCI,16,17 there are no guideline-based recommendations
for its regular utilization in the catheterization laboratory at present.
Acetylcholine testing
To assess the microvascular response to Ach, this endothelial agonist
is infused at increasing doses while CBF velocity is measured by
Doppler guidewire. The effect is expressed as the ratio of average
peak velocity (APV) of CBF during Ach administration over basal
APV. A concomitant assessment of the epicardial response to Ach is
usually done, to exclude the occurrence of epicardial spasm. Further
details on Ach test can be found in the Supplementary material on-
line, Addendum.
Result interpretation and cut-offs of acetylcholine-induced changes in
coronary blood flow
The coronary microvascular response to Ach is considered normal
when CBF increases by >50% compared to baseline,2,4,9,18,19 in
absence of significant epicardial constriction. Thus, an increase lower
than 50% indicates impaired coronary microvascular dilatation, but
some patients show CBF reduction, which suggests an abnormal cor-
onary microvascular constrictive response. Coronary microvascular
spasm (CMS) can also be diagnosed when angina and ischaemic elec-
trocardiogram (ECG) changes occur during Ach test in the absence
of significant epicardial spasm.13,20
Non-invasive assessment of coronary
microcirculation
In angina patients in whom flow-limiting coronary stenoses have been
excluded by angiography and by FFR, coronary microvascular dilator
function can be assessed non-invasively by various methods able to
provide estimates of coronary/myocardial blood flow at rest and dur-
ing maximal hyperaemia. In all cases, adenosine (140mg/kg/min intra-
venously) or dipyridamole (0.56–0.84mg intravenously) CFR is
usually measured and criteria for normal/abnormal values are the
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Take home figure The importance of an integrated approach to microvascular research. The potential contribution of microvascular dysfunc-
tion to a specific diseased condition or clinical presentation is suspected and confirmed through central microvascular assessment methods (for ex-
ample, by estimating the coronary flow reserve by left anterior descending transthoracic echocardiography). Subsequently, non-invasive,
reproducible peripheral microvascular assessment techniques might help the identification of potential risk factors associated with microvascular dys-
function in the specific diseased condition. Mechanistic studies can be used to confirm the impact of the putative risk factor and the specific pathways
through which it induces microvascular dysfunction. Finally, in situ studies performed on isolated arteries can be used to identify novel potential thera-
peutic targets. The use of drugs directed against such targets requires clinical validation, closing the circle of the microvascular research framework.
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































increased reactivity to constrictor stimuli, as indicated by a critical re-
duction of CBF in response to their administration, cannot adequate-
ly be assessed by non-invasive methods due to the impossibility to
exclude with certainty an involvement of epicardial vessels in the con-
strictor response.
Transthoracic Doppler echocardiography of the LAD coronary ar-
tery is a largely available and potentially widely applicable method to
assess CFR,21 but its use can be limited by technical issues and oper-
ator variability.22 Myocardial contrast echocardiography, on the
other hand, is a promising more objective ultrasound method to as-
sess CFR, but it has been used in only few studies until now and
requires further validation.23,24
PET and cardiac magnetic resonance (CMR) are the most reliable
methods for non-invasive assessment of coronary microvascular dila-
tion as they allow valuable measurements of global and regional myo-
cardial blood flow. Both methods have been validated in animal
models by microspheres blood flow studies, providing data for
physiological classification and diagnosis of perfusion abnormalities.25
Compared to PET, CMR shows a higher spatial resolution, lack of
ionizing radiations and guarantees an assessment of cardiac structure
and function (Table 1). However, the limited availability, high costs
and long execution times of these methods, make them poorly suit-
able for serial assessment of CMV function (Table 1). Further limita-
tions include radiation exposure for PET and, for CMR,
contraindication to gadolinium use in patients with glomerular filtra-
tion rate <30mL/min, claustrophobia, arrhythmias and implanted
devices.26
Methods of assessing peripheral
microvascular function/structure
The most validated and largely used techniques to measure micro-
vascular function and/or structure in the peripheral microcirculation
include forearm plethysmography, micromyography, finger plethys-
mography, and laser-Doppler flowmetry (LDF). Practical recommen-
dations for the selection of the most appropriate peripheral vascular
technique based on their strengths and limitations, as well as the re-
search question to be addressed, are provided in Table 2 and in the
Supplementary material online, Addendum.
Forearm plethysmography
This technique allows measurements in forearm blood flow (FBF)
changes by venous plethysmography before and after the infusion of
endothelium-dependent and -independent vasoactive substances
into a cannulated brachial artery.33 The absence of systemic effects of
the vasoactive drugs being tested is guaranteed by the lack of FBF
changes in the contralateral forearm and the constant rate of arterial
inflow.34,35 Details are reported in the Supplementary material on-
line, Addendum.
Venous plethysmography can also provide indirect information on
the structure of small resistance arteries by measuring the maximum
post-ischaemic flow. This is obtained by occlusion of the brachial ar-
tery of the dominant arm, followed by dynamic exercise (see the
Supplementary material online, Addendum file for further details).
Once the arterial occlusion is rapidly removed, the venous occlusion
is maintained. The increased volume of the forearm is proportional
to the maximal arterial flow capacity. The minimum vascular resistan-
ces are obtained by dividing the mean BP for the maximum arterial
flow. This measure correlates well with more direct measurements
of resistance vessel structure, such as the media-to-lumen ratio
(MLR) obtained with micromyography,36 and is not influenced by
sympathetic tone or administration of vasodilators.37
Cut-off of forearm blood flow and minimum forearm
vascular resistance
Although some studies have documented a relationship between
forearm endothelial function and risk of CV events,38,39 at present
clear cut-off values for abnormal FBF and minimum vascular resist-
ance are not available. Accordingly, the use of this technique remains
mainly limited to mechanistic studies.
Micromyography
This technique is performed in two major variants: wire and
perfusion-pressure micromyography. Both methods enable the as-
sessment of both functional and structural characteristics of isolated
resistance arterioles (100–300-mm lumen diameter), obtained from
subcutaneous tissue biopsies from the glutaeal or anterior abdominal
region.40–43 After isolation, vessels are cannulated with stainless steel
wires (wire micromyograph) or slipped into two glass microcannulae
contained in a pressurized chamber (pressurized myograph). Under
the direct visualization of the vessel by a microscope connected to a
computer, the endothelium-dependent and -independent relaxations
are assessed by measuring the dilatory responses to cumulative doses
of endothelial agonists (i.e. Ach) and sodium nitroprusside, respect-
ively.43,44Details on the recommended protocols are reported in the
Supplementary material online, Addendum.
The micromyography is the most widely used approach to evalu-
ate microvascular structural changes. The total wall thickness, as well
as the internal diameter of the vessels, can be evaluated by
computer-assisted video analysers.44 These data inform on the sever-
ity and the pattern of vascular remodelling induced by CV risk factor
exposure. Given its high sensitivity and specificity, MLR is the most
commonly used index of resistance artery remodelling, as it is inde-
pendent from the vessels’ dimensions,45,46 with no difference be-
tween wire or pressure micromyography.45,47,48 Conversely, media
thickness and internal diameters are dependent on vessel dimen-
sions;45 therefore, comparisons between such parameters need
caution.
Cut-off of media-to-lumen ratio
Age- and sex-specific percentiles of MLR in a healthy population have
been recently provided and should be used to discriminate healthy
subjects from those with early or advanced microvascular remodel-
ling (Supplementary material online, Table S1).40 Moreover, a cut-off
value of 0.098 has been shown in two studies to distinguish between
people with vs. those without CV events.49,50 In contrast, no studies
have documented a prognostic role for endothelial function, as eval-
uated by micromyography.
Finger plethysmography
This technique provides observer-independent measures of endo-
thelial function using peripheral arterial tonometry (PAT). The





































































































































































































































































technique captures beat-to-beat recordings of the finger arterial
pulse wave amplitude with pneumatic probes.51 A pressure cuff is
placed on one forearm and inflated to a supra-systolic pressure to
produce 5min of ischaemia followed by reactive hyperaemia. The
pneumatic probe applied to the fingertip of the same arm records
the increase in arterial blood volume, which is reflected by an in-
crease in pulsatile arterial column changes. The derived reactive
hyperaemia index (RHI) is considered a marker of endothelial func-
tion. Details of the recommended protocol are reported in the
Supplementary material online, Addendum.
An inverse relation between RHI and multiple CV risk factors has
been described,51–54 and a systematic meta-analysis has documented
that the RHI is as effective as flow-mediated dilation in predicting CV
events.55 However, it has been objected that RHI does not reflect
only endothelial function, as augmentation of the pulse amplitude
after reactive hyperaemia involves changes in flow that are only partly
(50%) dependent on NO availability.56 In addition, a poor correlation
has been reported between PAT and flow-mediated dilation in vari-
ous clinical settings.57,58
Cut-off of reactive hyperaemia index
Early studies have associated an RHI of >2.1 with a low risk of CV
events,59,60while values <1.5 have been associated with an increased
risk of CV events,61 particularly in subjects at moderate-to-high CV
risk or with angina symptoms. Other studies have confirmed that the
cut-off value of RHI that independently discriminate between sub-
jects at high or low risk for CV events ranges between 1.60 and
1.75.62,63
Laser-Doppler flowmetry
LDF provides a non-invasive real-time quantification of relative
changes in skin microcirculation. It is based on light-beating spectros-
copy and the detection of a Doppler shift of the laser light backscat-
tered from moving red blood cell in cutaneous microcirculation.64,65
The relative modifications in skin blood flow in response to endothe-
lial stimuli [usually post-occlusive reactive hyperaemia (PORH), local
thermal hyperaemia, Ach, or sodium nitroprusside iontophoresis]
are considered. LDF shows a good reproducibility (coefficient of vari-
ation <10%).66 Early studies suggested that PORH area is mainly
driven by the activation of sensory nerves and myogenic response.67
In turn, more recent reports have suggested that time to half before
and after hyperaemia (TH2) may represent a reliable marker of endo-
thelial function.68,69
Local thermal hyperaemia approach leads to a temperature-
dependent sustained increase in skin cutaneous flow. The plateau is
mostly mediated by NO and endothelium-derived hyperpolarizing
factor (EDHF),70while the initial rapid phase relies predominantly on
local sensory nerves.71 The contributions of neural reflex, NO, and
EDHF vary according to the target temperature and rate of heating.
A rapid heating to 39C seems to cause an almost exclusively NO-
dependent hyperaemia.72
Iontophoresis can be used to test the influence on the LDF signal
of vasoactive compounds. Ach and sodium nitroprusside might be
used to generate endothelium-dependent and -independent vasodila-
tation, respectively. Some authors, however, showed that a large part
of the Ach-related increase in blood flow is mediated by prostanoids
with only a modest attenuation by NO synthase inhibition.73 Others,
instead, confirmed that Ach-mediated vasodilation is highly NO de-
pendent, showing also an important interactions of NO with prosta-
glandins.74 Of note, methacholine seems to induce a more specific
NO-dependent vasodilation.75
Cut-off of laser-Doppler flowmetry
The LDF does not provide measures of absolute perfusion values.
Measurements are expressed as arbitrary perfusion unit (PU) or in
millivolts (1 PU = 10mV). To account for BP variations, most authors
present results as cutaneous vascular conductance, dividing blood
flow by mean BP values (mV/mm Hg).76 The non-specific responses
to iontophoresis and different methods used to acquire and elabor-
ate the results make difficult the identification of normal values for
LDF; furthermore, it remains unclear whether LDF measurements
have any additional value in predicting CV events.
Molecular mechanisms of
microvascular disease: oxidative
stress and inflammation drive
microvascular ageing
Reactive oxygen species (ROS) and the inflammatory response can
be considered final common pathways leading to microvascular dys-
function consequent to CV risk factor exposure. Increasing evidence
supports a tight and highly dynamic regulation of inflammatory and
redox-signalling pathways induced by inflammatory, metabolic, and
haemodynamic changes at the level of the microcirculation. Many of
these pathways are also involved in the control of cellular ageing and
apoptosis and, in animal experiments, their modulation can induce
substantial changes in the lifespan, ultimately supporting a relevant
contribution of an inflammageing process to the evolution of micro-
vascular dysfunction.
The mitochondrial adaptor p66Shc has emerged as a pivotal modu-
lator of mitochondrial ROS production, inflammation, and vascular
aging.77 Several CV risk factors have been shown to induce p66Shc
up-regulation, leading to premature ROS accumulation, senescence,
and endothelial dysfunction in mice and humans77 (Figure 1). Genetic
deletion of p66Shc prevents age-dependent endothelial dysfunction
and extends lifespan by 30% in mice.78–80 Activation of Arginase II
(Arg II), the enzyme that metabolizes the eNOS substrate L-arginine
to urea and L-ornithine, also represents an important link between
CV risk factors and microvascular aging. Arg II activity is increased in
patients with type 2 diabetes (T2DM) and hypertension, where
accounts for reduced L-arginine availability, decreased NO produc-
tion, and endothelial dysfunction.81 It also triggers vascular senes-
cence in VSMCs and endothelial cells.82 Arginase inhibition restores
endothelial-dependent vasorelaxation in small arteries of obese
patients, although this effect is attenuated in ageing due to a high pro-
oxidant environment sustained by hyperactivation of the NADPH
oxidase (Nox).41,83
The family of Nox enzymes is another major source of micro-
vascular ROS. Clinical conditions associated to the perturbation of
microvascular haemodynamic and metabolic homeostasis are charac-
terized by increased vascular reactivity and overexpression of





































































































.different Nox isoforms, which has been implicated in the develop-
ment of an early microvascular ageing phenotype.41,84 Furthermore,
inflammatory cytokines [i.e. tumour necrosis factor alpha (TNF-a)
and interleukin-6] are often elevated in patients with cardiometabolic
disturbances and associate with the augmented activity of Nox and
vascular aging.85 Sirtuins (a family of nicotinamide adenine
dinucleotide-dependent proteins) represent another example of the
connection between oxidative stress and ageing pathways at the level
of the microcirculation. Age-related loss of SIRT1 leads to functional
deficits, diminishes stress response, reduces capacity for migration/
Figure 1 Major pathways leading to ROS-mediated microvascular dysfunction. Nox isoforms and mitochondria represent major systems account-
ing for the dynamic regulation of ROS production within the microvascular wall. The activation of Nox leads to ROS production and triggers p66Shc
phosphorylation and translocation within the mitochondria, where it further promotes ROS generation by altering the function of the mitochondria
respiratory chain and opening the mitochondria permeability transition pore. In turn, p66Shc activation stimulates the activity of Nox, thus generating
a vicious cycle that amplifies ROS production. The increased concentration of intracellular ROS promotes the transformation of NO in peroxynitrite
radicals and uncouples the eNOS, switching its activity from a NO to a ROS producing enzyme. Epigenetic modifications commonly detected in age-
ing, such as a reduced SIRT1 expression, sustain a further increase in intracellular oxidative stress, reducing the expression of antioxidant enzymes
(secondary to FOXO inhibition) and promoting pro-inflammatory cytokine production through activation of the NF-kB and expression of adhesion
molecules. NO, nitric oxide; NoX, NADPH oxidase; ROS, reactive oxygen species.





































































































































































































































































proliferation, and increases senescence by modulating several down-
stream effectors including LKB1, AMPK, and FOXO.86 Moreover,
microRNA-217 suppresses SIRT1-dependent eNOS functionality
and triggers endothelial senescence.87
The increased ROS generation at the level of the microvascular
wall is also a potent activator of the inflammatory response. ROS acti-
vate mitogen-activated protein kinases (ERK1/2, p38MAPK, and
JNK), tyrosine kinases, and tyrosine phosphatases, which control
vascular cell proliferation, migration, hypertrophy, and inflamma-
tion.88–90 Important downstream redox targets are transcription fac-
tors (NF-kB, AP-1 and HIF-1) and pro-inflammatory genes, critically
involved in chemokine and cytokine production, recruitment, and ac-
tivation of inflammatory and immune cells, which promote micro-
vascular inflammation and fibrosis in response to CV risk factors.89
Indeed, human studies showed an inverse relationship between per-
ipheral microvascular structural changes and circulating Treg lympho-
cytes.91 In addition, subpopulations of circulating T lymphocytes are
associated with microvascular oxidative stress in peripheral human
arteries.91
Epigenetic regulation of microvascular
function
Epigenetic changes or mutations are emerging as key mechanisms
underpinning the dynamic ability of the microcirculation to modulate
inflammation, oxidative stress, and ageing signalling in response to
changes in the local metabolic and haemodynamic environment.92
Some of most intensively studied epigenetic changes involved in oxi-
dative stress-mediated microvascular dysfunction relate to the p66Shc
gene. Epigenetic remodelling of p66Shc promoter by DNA methyla-
tion and histone modifications is involved in obesity and diabetes-
induced oxidative stress, endothelial dysfunction, and vascular
hyperglycaemic memory, the phenomenon responsible for persistent
oxidative stress and vascular dysfunction despite the achievement of
an optimal glycaemic control.93–95 Reduced DNA methylation and
increased methylation of histone at lysine 4 (H3K4) were found on
the promoter of TNFa, a pro-inflammatory cytokine involved in
obesity and hypertension-related microvascular dysfunction.96,97
Similarly, activation of the methyltransferase SUV39H1 in VSMCs
from diabetic mice was found to regulate the pro-inflammatory tran-
scription factor NF-kB p65.98 Furthermore, mono-methylation of his-
tone 3 at lysine 4 (H3K4me1) by the methyltransferase SETD7
fosters endothelial inflammation, senescence, and vascular dysfunc-
tion via up-regulation of NF-kB p65 and p53.99 Besides the modifica-
tions in chromatin, several miRNAs (miR-92, miR-126, miR-195, miR
26a, and miR-155) are implicated in microvascular dysfunction by tar-
geting relevant pathways involved in endothelial cell and VSMC dam-
age (i.e. eNOS, RhoA, Smad1, Sirt1, Bcl-2).100 The importance of
these epigenetic discoveries is supported by the recent development
of epigenetic pharmacological intervention. The histone deacetylase
inhibitor Vorinostat has shown to prevent NF-kB activation, eNOS
uncoupling, and vascular oxidative stress in diabetic mice.101 Similarly,
histone deacetylase blockade by Trichostatin A and sodium butyrate
prevented TNF-a transcription while promoting angiogenic re-
sponse.102 Apabetalone—an epigenetic regulator targeting bromo-
domain and extra-terminal proteins—modulates vascular
inflammation and reduces CV events.103 Also, miRs targeting, by
mimics or antagomiRs, is a promising epigenetic therapy currently




Many studies have shown that CMD can be responsible for both
chronic and acute myocardial ischaemic syndromes.106,107 The
microvascular origin of ischaemic symptoms should be suspected in
patients with the evidence of myocardial ischaemia at non-invasive in-
vestigation who show no obstructive stenosis (usually >_50%) and no
other specific causes of ischaemia (e.g. epicardial spasm, intracoro-
nary thrombus, coronary dissection) at coronary angiography, but it
is definitely demonstrated by confirming the presence of CMD.13
MVA [and asymptomatic myocardial ischaemia with non-
obstructed coronary arteries (INOCAs)] may occur in the context
of various heart diseases,108 but it also represents the main or specific
cardiac issue for many patients (primary MVA). Stable MVA, mainly
related to efforts, is the most typical clinical presentation.106 Both an
impairment of coronary microvascular dilatation and an increased
coronary microvascular constriction have been demonstrated and
may variably contribute to the symptoms in these patients.109–112
The initial treatment of stable MVA is based on traditional anti-
ischaemic drugs (beta-blockers, calcium antagonists, nitrates). These,
however, fail to obtain a satisfactory control of angina symptoms in a
sizeable proportion of patients.113,114 Thus, several additional drugs
(e.g. ranolazine, xanthines, ivabradine, trimetazidine) and non-
pharmacological therapies (e.g. spinal cord stimulation, enhanced ex-
ternal counterpulsation) have been proposed and may help achieve
significant angina relief.115,116 Importantly, the recent CorMicA trial
has shown that, in patients with angina but non-obstructive CAD,
pharmacological therapy guided by the results of invasive provocative
testing, aimed to identify the pathophysiological mechanism(s) re-
sponsible for the symptoms, may result in better symptom control,
as compared with empiric choices.117
Prognosis of stable MVA is debated. Studies including patients with
NCAs have consistently shown good clinical outcome.113,114,118,119
Some reports, however, have described increased rates of clinical
events in angina patients with non-obstructive coronary sten-
oses120,121 or a relation between CMD and events.9,122,123 The inter-
pretation of these results is complicated by the recruitment of
heterogeneous populations, in whom the role of CMD as an inde-
pendent causal factor was not assessed appropriately. Furthermore,
the relation of CMD with outcome was not consistent among stud-
ies.9,122–125 Thus, whether CMD adds prognostic information in
patients with non-significant stenosis requires further assessment.126
Most recently, CMS has been suggested to be a cause of the clinical
picture of acute coronary syndrome (ACS) with non-obstructed cor-
onary arteries at angiography, who constitute 10–15% of those
admitted with a diagnosis of ACS and include patients with myocar-
dial infarction with non-obstructed coronary arteries
(MINOCAs).13,106,127 The mechanisms of these ACSs, however, are
heterogeneous, and the prevalence of CMS-related ACSs remains to
be established.128 In a study, 16.3% of 80 MINOCA patients129 had





































































































































































































































































evidence of CMS on Ach testing, which was associated with a worse
clinical outcome. However, most patients with events also had epi-
cardial spasm and, therefore, the exact prognostic role of CMS in this
context also remains to be better defined.
No established treatment for either acute INOCA or MINOCA is
available at present, due to the different pathophysiological mecha-
nisms responsible for the syndrome and the lack of clinical trials.
Some benefits on CV events have been reported in a retrospective
study by statins, beta-blockers, and inhibitors of the renin–angioten-
sin system,130 but calcium antagonists are expected to be the main
treatment for recurrent angina episodes related to CMS.131
Finally, recent data suggest that CMD may be involved in the
mechanisms responsible for heart failure with preserved left ventricu-
lar ejection fraction,132 although prospective studies relating CMD to
the development of this clinical condition are still lacking.
Peripheral microcirculation
Some studies showed that peripheral microvascular endothelial dys-
function might be a powerful predictor of CV events in both subjects
at high or low CV risk.38,39 In particular, the RHI and the hyperaemic
velocity (considered an indirect marker of microvascular function)
confirmed that the severity of endothelial dysfunction at the forearm
microcirculation can predict the risk of future CV events.61,133,134
Microvascular structural changes also provide reliable prognostic
information. Structural alterations in the subcutaneous vascular dis-
trict are, indeed, a good reflection of those detectable in target
organs, including heart135 and brain.136 This might lead to impaired
organ flow reserve and, as such, could account for the faster progres-
sion of organ damage and the increased CV risk of diabetic and
hypertensive patients.137,138 An increased MLR is also a powerful and
independent predictor of adverse CV outcome.49,50,139
There is evidence suggesting that interventions on advanced
microvascular disease burden are less effective than early treat-
ments.140 Indeed, individuals with high MLR remain at increased CV
risk despite normalization of BP values.141 Instead, early CV interven-
tions have significant impact on peripheral artery remodelling,142–144
potentially leading to improved tissue perfusion and regression of
organ damage.142 Also, more aggressive interventions are needed to
reduce the burden of microvascular remodelling in patients with
advanced disease.145
Conclusions
The increasing use of invasive and non-invasive coronary and periph-
eral microvascular assessment methods has unravelled the role of
microvascular dysfunction in several CV disease manifestations. In
parallel, a better understanding of the biological mechanisms involved
in microvascular dysfunction has shown that regulation of the micro-
vascular phenotype is highly dynamic and tightly regulated by local
levels of inflammation and oxidative stress. Epigenetic modifications
are emerging as key mechanisms of post-natal microvascular adapta-
tion to different environmental factors and have highlighted the sub-
stantial overlap between inflammatory, oxidative stress, metabolic
and cellular ageing pathways in the regulation of the microcirculation
phenotype. Despite these advancements, no microvascular active
drugs are available at present. This is related to several factors,
including the difficulties in creating large datasets of microvascular
data acquired using standardized protocols and the limited integra-
tion of the data obtained from central and peripheral microvascular
methods. The refinement of microvascular assessment techniques
and standardization of their protocols, combined with the availability
of specific prognostic cut-off values, provide now a unique opportun-
ity to move microvascular research from the bench to a clinical set-
ting, potentially allowing the earlier identification of patients at high
CV risk. Furthermore, the adoption of a more integrated approach
to microvascular research in the future, whereby central and periph-
eral microvascular assessments are performed as part of the same
study, has the potential to accelerate the identification of novel and
disease-specific therapeutic targets and the development of drugs
that could be used to prevent the evolution and clinical consequen-
ces of microvascular disease.
Supplementary material
Supplementary material is available at European Heart Journal online.
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dependent cerebrovascular dysfunction is mediated by adaptor protein p66Shc.
Int J Cardiol 2014;175:446–450.
80. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone
L, Pelicci PG. The p66shc adaptor protein controls oxidative stress response
and life span in mammals. Nature 1999;402:309–313.
81. Mahdi A, Kovamees O, Pernow J. Improvement in endothelial function in car-
diovascular disease - Is arginase the target? Int J Cardiol 2020;301:207–214.
82. Paneni F, Costantino S, Cosentino F. Molecular pathways of arterial aging. Clin
Sci (Lond) 2015;128:69–79.
83. Shemyakin A, Kovamees O, Rafnsson A, Bohm F, Svenarud P, Settergren M,
Jung C, Pernow J. Arginase inhibition improves endothelial function in patients
with coronary artery disease and type 2 diabetes mellitus. Circulation 2012;126:
2943–2950.
84. Bruno RM, Duranti E, Ippolito C, Segnani C, Bernardini N, Di Candio G,
Chiarugi M, Taddei S, Virdis A. Different impact of essential hypertension on
structural and functional age-related vascular changes. Hypertension 2017;69:
71–78.
85. Paneni F, Diaz Canestro C, Libby P, Luscher TF, Camici GG. The aging cardio-
vascular system: understanding it at the cellular and clinical levels. J Am Coll
Cardiol 2017;69:1952–1967.
86. Winnik S, Auwerx J, Sinclair DA, Matter CM. Protective effects of sirtuins in
cardiovascular diseases: from bench to bedside. Eur Heart J 2015;36:3404–3412.
87. Menghini R, Casagrande V, Cardellini M, Martelli E, Terrinoni A, Amati F, Vasa-
Nicotera M, Ippoliti A, Novelli G, Melino G, Lauro R, Federici M. MicroRNA
217 modulates endothelial cell senescence via silent information regulator 1.
Circulation 2009;120:1524–1532.
88. Xu Q, Huff LP, Fujii M, Griendling KK. Redox regulation of the actin cytoskel-
eton and its role in the vascular system. Free Radic Biol Med 2017;109:84–107.
89. Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and
redox regulation in cellular signaling. Cell Signal 2012;24:981–990.
90. Tabet F, Schiffrin EL, Touyz RM. Mitogen-activated protein kinase activation by
hydrogen peroxide is mediated through tyrosine kinase-dependent, protein kin-
ase C-independent pathways in vascular smooth muscle cells: upregulation in
spontaneously hypertensive rats. J Hypertens 2005;23:2005–2012.
91. De Ciuceis C, Agabiti-Rosei C, Rossini C, Airo P, Scarsi M, Tincani A, Tiberio
GAM, Piantoni S, Porteri E, Solaini L, Duse S, Semeraro F, Petroboni B, Mori L,
Castellano M, Gavazzi A, Agabiti-Rosei E, Rizzoni D. Relationship between dif-
ferent subpopulations of circulating CD4þ T lymphocytes and microvascular or
systemic oxidative stress in humans. Blood Press 2017;26:237–245.
92. Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and
role in cardiovascular disease. Circulation 2011;123:2145–2156.
93. Costantino S, Paneni F, Virdis A, Hussain S, Mohammed SA, Capretti G,
Akhmedov A, Dalgaard K, Chiandotto S, Pospisilik JA, Jenuwein T, Giorgio M,
Volpe M, Taddei S, Luscher TF, Cosentino F. Interplay among H3K9-editing
enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascu-
lar oxidative stress in obesity. Eur Heart J 2019;40:383–391.
94. Costantino S, Paneni F, Battista R, Castello L, Capretti G, Chiandotto S, Tanese
L, Russo G, Pitocco D, Lanza GA, Volpe M, Luscher TF, Cosentino F. Impact of
glycemic variability on chromatin remodeling, oxidative stress, and endothelial
dysfunction in patients with type 2 diabetes and with target HbA1c levels.
Diabetes 2017;66:2472–2482.
95. Paneni F, Mocharla P, Akhmedov A, Costantino S, Osto E, Volpe M, Luscher
TF, Cosentino F. Gene silencing of the mitochondrial adaptor p66(Shc) sup-
presses vascular hyperglycemic memory in diabetes. Circ Res 2012;111:
278–289.































































































































































































































































96. Sullivan KE, Reddy AB, Dietzmann K, Suriano AR, Kocieda VP, Stewart M,
Bhatia M. Epigenetic regulation of tumor necrosis factor alpha. Mol Cell Biol
2007;27:5147–5160.
97. Virdis A, Duranti E, Rossi C, Dell’Agnello U, Santini E, Anselmino M, Chiarugi
M, Taddei S, Solini A. Tumour necrosis factor-alpha participates on the
endothelin-1/nitric oxide imbalance in small arteries from obese patients: role
of perivascular adipose tissue. Eur Heart J 2015;36:784–794.
98. Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, Calkin
AC, Brownlee M, Cooper ME, El-Osta A. Hyperglycemia induces a dynamic
cooperativity of histone methylase and demethylase enzymes associated with
gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009;
58:1229–1236.
99. Okabe J, Orlowski C, Balcerczyk A, Tikellis C, Thomas MC, Cooper ME, El-
Osta A. Distinguishing hyperglycemic changes by Set7 in vascular endothelial
cells. Circ Res 2012;110:1067–1076.
100. Zhang Y, Sun X, Icli B, Feinberg MW. Emerging roles for microRNAs in diabetic
microvascular disease: novel targets for therapy. Endocr Rev 2017;38:145–168.
101. Advani A, Huang Q, Thai K, Advani SL, White KE, Kelly DJ, Yuen DA, Connelly
KA, Marsden PA, Gilbert RE. Long-term administration of the histone deacety-
lase inhibitor vorinostat attenuates renal injury in experimental diabetes
through an endothelial nitric oxide synthase-dependent mechanism. Am J Pathol
2011;178:2205–2214.
102. Paneni F, Costantino S, Battista R, Castello L, Capretti G, Chiandotto S,
Scavone G, Villano A, Pitocco D, Lanza G, Volpe M, Luscher TF, Cosentino F.
Adverse epigenetic signatures by histone methyltransferase Set7 contribute to
vascular dysfunction in patients with type 2 diabetes mellitus. Circ Cardiovasc
Genet 2015;8:150–158.
103. Nicholls SJ, Ray KK, Johansson JO, Gordon A, Sweeney M, Halliday C,
Kulikowski E, Wong N, Kim SW, Schwartz GG. Selective BET protein inhibition
with apabetalone and cardiovascular events: a pooled analysis of trials in
patients with coronary artery disease. Am J Cardiovasc Drugs 2018;18:109–115.
104. Poller W, Dimmeler S, Heymans S, Zeller T, Haas J, Karakas M, Leistner DM,
Jakob P, Nakagawa S, Blankenberg S, Engelhardt S, Thum T, Weber C, Meder B,
Hajjar R, Landmesser U. Non-coding RNAs in cardiovascular diseases: diagnos-
tic and therapeutic perspectives. Eur Heart J 2018;39:2704–2716.
105. Landmesser U, Poller W, Tsimikas S, Most P, Paneni F, Luscher TF. From trad-
itional pharmacological towards nucleic acid-based therapies for cardiovascular
diseases. Eur Heart J 2020;
106. Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presen-
tation, pathophysiology, and management. Circulation 2010;121:2317–2325.
107. Ford TJ, Corcoran D, Padmanabhan S, Aman A, Rocchiccioli P, Good R,
McEntegart M, Maguire JJ, Watkins S, Eteiba H, Shaukat A, Lindsay M,
Robertson K, Hood S, McGeoch R, McDade R, Yii E, Sattar N, Hsu LY, Arai AE,
Oldroyd KG, Touyz RM, Davenport AP, Berry C. Genetic dysregulation of
endothelin-1 is implicated in coronary microvascular dysfunction. Eur Heart J
2020;41:3239–3252.
108. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;
356:830–840.
109. Bottcher M, Botker HE, Sonne H, Nielsen TT, Czernin J. Endothelium-depend-
ent and -independent perfusion reserve and the effect of L-arginine on myocar-
dial perfusion in patients with syndrome X. Circulation 1999;99:1795–1801.
110. Chauhan A, Mullins PA, Taylor G, Petch MC, Schofield PM. Effect of hyperventi-
lation and mental stress on coronary blood flow in syndrome X. Br Heart J
1993;69:516–524.
111. Lanza GA, Buffon A, Sestito A, Natale L, Sgueglia GA, Galiuto L, Infusino F,
Mariani L, Centola A, Crea F. Relation between stress-induced myocardial per-
fusion defects on cardiovascular magnetic resonance and coronary microvascu-
lar dysfunction in patients with cardiac syndrome X. J Am Coll Cardiol 2008;51:
466–472.
112. Ohba K, Sugiyama S, Sumida H, Nozaki T, Matsubara J, Matsuzawa Y, Konishi
M, Akiyama E, Kurokawa H, Maeda H, Sugamura K, Nagayoshi Y, Morihisa K,
Sakamoto K, Tsujita K, Yamamoto E, Yamamuro M, Kojima S, Kaikita K, Tayama
S, Hokimoto S, Matsui K, Sakamoto T, Ogawa H. Microvascular coronary artery
spasm presents distinctive clinical features with endothelial dysfunction as non-
obstructive coronary artery disease. J Am Heart Assoc 2012;1:e002485.
113. Kaski JC, Rosano GM, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson
PA. Cardiac syndrome X: clinical characteristics and left ventricular function.
Long-term follow-up study. J Am Coll Cardiol 1995;25:807–814.
114. Lamendola P, Lanza GA, Spinelli A, Sgueglia GA, Di Monaco A, Barone L,
Sestito A, Crea F. Long-term prognosis of patients with cardiac syndrome X. Int
J Cardiol 2010;140:197–199.
115. Lanza GA, Parrinello R, Figliozzi S. Management of microvascular angina pecto-
ris. Am J Cardiovasc Drugs 2014;14:31–40.
116. Boari GE, Rizzardi N, de Ciuceis C, Platto C, Paiardi S, Porteri E, Paini A,
Salvetti M, Muiesan ML, Rizzoni D, Rosei EA. Determinants of the structure of
resistance-sized arteries in hypertensive patients. Blood Press 2008;17:204–211.
117. Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, Eteiba H,
Shaukat A, Lindsay M, Robertson K, Hood S, McGeoch R, McDade R, Yii E,
Sidik N, McCartney P, Corcoran D, Collison D, Rush C, McConnachie A,
Touyz RM, Oldroyd KG, Berry C. Stratified medical therapy using invasive cor-
onary function testing in angina: the CorMicA trial. J Am Coll Cardiol 2018;72:
2841–2855.
118. Radico F, Zimarino M, Fulgenzi F, Ricci F, Di Nicola M, Jespersen L, Chang SM,
Humphries KH, Marzilli M, De Caterina R. Determinants of long-term clinical
outcomes in patients with angina but without obstructive coronary artery dis-
ease: a systematic review and meta-analysis. Eur Heart J 2018;39:2135–2146.
119. Lanza GA, Filice M, De Vita A, Lamendola P, Villano A, Spera F, Golino M, Rota
E, Argiro A, Crea F. Primary stable microvascular angina: a long-term clinical
follow-up study. Circulation 2017;135:1982–1984.
120. Gulati M, Cooper-DeHoff RM, McClure C, Johnson BD, Shaw LJ, Handberg EM,
Zineh I, Kelsey SF, Arnsdorf MF, Black HR, Pepine CJ, Merz CN. Adverse car-
diovascular outcomes in women with nonobstructive coronary artery disease: a
report from the Women’s Ischemia Syndrome Evaluation Study and the St
James Women Take Heart Project. Arch Intern Med 2009;169:843–850.
121. Jespersen L, Hvelplund A, Abildstrom SZ, Pedersen F, Galatius S, Madsen JK,
Jorgensen E, Kelbaek H, Prescott E. Stable angina pectoris with no obstructive
coronary artery disease is associated with increased risks of major adverse car-
diovascular events. Eur Heart J 2012;33:734–744.
122. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA,
Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dys-
function. Circulation 2002;106:653–658.
123. Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, Johnson
BD, Sopko G, Bairey Merz CN. Coronary microvascular reactivity to adenosine
predicts adverse outcome in women evaluated for suspected ischemia results
from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia
Syndrome Evaluation) study. J Am Coll Cardiol 2010;55:2825–2832.
124. AlBadri A, Bairey Merz CN, Johnson BD, Wei J, Mehta PK, Cook-Wiens G, Reis
SE, Kelsey SF, Bittner V, Sopko G, Shaw LJ, Pepine CJ, Ahmed B. Impact of ab-
normal coronary reactivity on long-term clinical outcomes in women. J Am Coll
Cardiol 2019;73:684–693.
125. von Mering GO, Arant CB, Wessel TR, McGorray SP, Bairey Merz CN, Sharaf
BL, Smith KM, Olson MB, Johnson BD, Sopko G, Handberg E, Pepine CJ,
Kerensky RA; National Heart Lung, and Blood Institute. Abnormal coronary
vasomotion as a prognostic indicator of cardiovascular events in women: results
from the National Heart, Lung, and Blood Institute-Sponsored Women’s
Ischemia Syndrome Evaluation (WISE). Circulation 2004;109:722–725.
126. Lanza GA, Crea F, Kaski JC. Clinical outcomes in patients with primary stable
microvascular angina: is the jury still out? Eur Heart J Qual Care Clin Outcomes
2019;5:283–291.
127. Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM,
Lerman A, Cushman M, Kumbhani DJ, Arslanian-Engoren C, Bolger AF,
Beltrame JF; American Heart Association Interventional Cardiovascular Care
Committee of the Council on Clinical Cardiology; Council on Cardiovascular
and Stroke Nursing; Council on Epidemiology and Prevention; and Council on
Quality of Care and Outcomes Research. Contemporary diagnosis and manage-
ment of patients with myocardial infarction in the absence of obstructive cor-
onary artery disease: a scientific statement from the American Heart
Association. Circulation 2019;139:e891–e908.
128. Lanza GA, Careri G, Stazi A, Villano A, De Vita A, Aurigemma C, Crea F.
Clinical spectrum and outcome of patients with non-ST-segment elevation
acute coronary syndrome and no obstructive coronary atherosclerosis. Circ J
2016;80:1600–1606.
129. Montone RA, Niccoli G, Fracassi F, Russo M, Gurgoglione F, Camma G, Lanza
GA, Crea F. Patients with acute myocardial infarction and non-obstructive cor-
onary arteries: safety and prognostic relevance of invasive coronary provocative
tests. Eur Heart J 2018;39:91–98.
130. Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjold A, Gard A,
Jernberg T. Medical therapy for secondary prevention and long-term outcome
in patients with myocardial infarction with nonobstructive coronary artery dis-
ease. Circulation 2017;135:1481–1489.
131. Beltrame JF, Turner SP, Leslie SL, Solomon P, Freedman SB, Horowitz JD. The
angiographic and clinical benefits of mibefradil in the coronary slow flow phe-
nomenon. J Am Coll Cardiol 2004;44:57–62.
132. Crea F, Bairey Merz CN, Beltrame JF, Kaski JC, Ogawa H, Ong P, Sechtem U,
Shimokawa H, Camici PG; Coronary Vasomotion Disorders International Study














































































































































Group. The parallel tales of microvascular angina and heart failure with pre-
served ejection fraction: a paradigm shift. Eur Heart J 2017;38:473–477.
133. Anderson TJ, Charbonneau F, Title LM, Buithieu J, Rose MS, Conradson H,
Hildebrand K, Fung M, Verma S, Lonn EM. Microvascular function predicts car-
diovascular events in primary prevention: long-term results from
the Firefighters and Their Endothelium (FATE) study. Circulation 2011;123:
163–169.
134. Matsuzawa Y, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Konishi M,
Matsubara J, Sumida H, Kaikita K, Kojima S, Nagayoshi Y, Yamamuro M, Izumiya
Y, Iwashita S, Matsui K, Jinnouchi H, Kimura K, Umemura S, Ogawa H. Digital
assessment of endothelial function and ischemic heart disease in women. J Am
Coll Cardiol 2010;55:1688–1696.
135. Rizzoni D, Palombo C, Porteri E, Muiesan ML, Kozakova M, La Canna G, Nardi
M, Guelfi D, Salvetti M, Morizzo C, Vittone F, Rosei EA. Relationships between
coronary flow vasodilator capacity and small artery remodelling in hypertensive
patients. J Hypertens 2003;21:625–631.
136. Rizzoni D, De Ciuceis C, Porteri E, Paiardi S, Boari GE, Mortini P, Cornali C,
Cenzato M, Rodella LF, Borsani E, Rizzardi N, Platto C, Rezzani R, Rosei EA.
Altered structure of small cerebral arteries in patients with essential hyperten-
sion. J Hypertens 2009;27:838–845.
137. Agabiti-Rosei E, Rizzoni D. Microvascular structure as a prognostically relevant
endpoint. J Hypertens 2017;35:914–921.
138. Heagerty AM. Predicting hypertension complications from small artery struc-
ture. J Hypertens 2007;25:939–940.
139. Rizzoni D, Porteri E, Boari GE, De Ciuceis C, Sleiman I, Muiesan ML, Castellano
M, Miclini M, Agabiti-Rosei E. Prognostic significance of small-artery structure in
hypertension. Circulation 2003;108:2230–2235.
140. Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, Tiberio GA,
Giulini SM, Agabiti-Rosei E, Pessina AC. Vascular remodeling and duration of
hypertension predict outcome of adrenalectomy in primary aldosteronism
patients. Hypertension 2008;51:1366–1371.
141. Buus NH, Mathiassen ON, Fenger-Gron M, Praestholm MN, Sihm I, Thybo NK,
Schroeder AP, Thygesen K, Aalkjaer C, Pedersen OL, Mulvany MJ, Christensen KL.
Small artery structure during antihypertensive therapy is an independent predictor
of cardiovascular events in essential hypertension. J Hypertens 2013;31:791–797.
142. Buus NH, Bottcher M, Jorgensen CG, Christensen KL, Thygesen K, Nielsen TT,
Mulvany MJ. Myocardial perfusion during long-term angiotensin-converting en-
zyme inhibition or beta-blockade in patients with essential hypertension.
Hypertension 2004;44:465–470.
143. Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting en-
zyme inhibitor on resistance arteries in essential hypertension. Hypertension
1994;23:83–91.
144. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure
and endothelial dysfunction in human essential hypertension by the angiotensin
receptor antagonist losartan. Circulation 2000;101:1653–1659.
145. Savoia C, Touyz RM, Endemann DH, Pu Q, Ko EA, De Ciuceis C, Schiffrin EL.
Angiotensin receptor blocker added to previous antihypertensive agents on
arteries of diabetic hypertensive patients. Hypertension 2006;48:271–277.
Evaluation of microvascular disease in humans 15
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/e
u
rh
e
a
rtj/a
d
v
a
n
c
e
-a
rtic
le
/d
o
i/1
0
.1
0
9
3
/e
u
rh
e
a
rtj/e
h
a
a
8
5
7
/6
0
1
2
9
2
8
 b
y
 g
u
e
s
t o
n
 2
3
 M
a
rc
h
 2
0
2
1
